What happens when you stop a GLP-1?

By the Modern Weight Medicine editorial team Published Jul 11, 2026 7 sources How we verify

The short answer

As of July 11, 2026

When you stop a GLP-1 medication, most people gradually regain a large share of the weight they lost, because the medication's appetite-lowering effect ends and the underlying biology of obesity reasserts itself. In the STEP 1 trial extension, people who had lost 17.3% of their body weight on semaglutide regained about two-thirds of it in the year after stopping, ending 5.6% below their starting weight. Randomized withdrawal trials of both semaglutide (STEP 4) and tirzepatide (SURMOUNT-4) show the same pattern, and the improvements in blood pressure and lipids drift back toward baseline as the weight returns. Continuing treatment maintained and even added to the weight loss in those trials. This is why obesity medicine treats these drugs as long-term therapy, and why a decision to stop, taper, or continue belongs with a licensed provider, a prescription is never promised in advance.

When you stop a GLP-1 medication, most people gradually regain a large share of the weight they lost. The medication’s effect on appetite ends, hunger returns, and the biology that drove the weight up in the first place reasserts itself. The most useful thing to understand before you start or stop one of these drugs is that the randomized trials were designed to answer exactly this question, and their answer is consistent. This page walks through what those withdrawal trials found for both semaglutide and tirzepatide, why the weight comes back, and what that means for maintenance. For the bigger picture on long-term dosing, see our guide to GLP-1 maintenance and microdosing.

How much weight do people regain after stopping semaglutide?

People regain roughly two-thirds of their lost weight in the year after stopping semaglutide, according to the STEP 1 trial extension. In the original STEP 1 trial, participants lost a mean of 17.3% of their body weight over 68 weeks on once-weekly semaglutide 2.4 mg. After the medication and its lifestyle program were withdrawn, the semaglutide group in the extension regained 11.6 percentage points of that loss by week 120, one year after stopping, leaving a net loss of 5.6% from where they started (Wilding et al., STEP 1 trial extension, Diabetes, Obesity and Metabolism 2022). At that one-year mark, 48.2% of the semaglutide group were still at least 5% below their original weight, so the regain was substantial but not always complete (STEP 1 extension full text). The authors concluded that the findings “confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health.”

What happens when you stop tirzepatide (Zepbound or Mounjaro)?

Stopping tirzepatide produces the same pattern of regain, shown directly in the SURMOUNT-4 randomized trial. Participants first took tirzepatide for a 36-week open-label lead-in at the maximum tolerated dose of 10 or 15 mg and lost a mean of 20.9% of their body weight. They were then randomly assigned to keep taking tirzepatide or switch to placebo. From randomization at week 36 to week 88, the people who continued lost a further 5.5% on average, while those switched to placebo regained weight, gaining 14.0%, a difference of 19.4 percentage points between continuing and stopping (Aronne et al., SURMOUNT-4, JAMA 2024). The trial’s conclusion was direct: “withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and augmented initial weight reduction.”

Why does the weight come back after you stop?

The weight returns because a GLP-1 medication manages the drivers of obesity rather than curing them, so removing it removes the effect. These medications work by acting on GLP-1 receptors to reduce appetite and slow stomach emptying, which lowers how much you eat; the branded weight-management products are indicated “to reduce excess body weight and maintain weight reduction long term,” not for a fixed course (Wegovy Prescribing Information, DailyMed). When the drug clears, appetite and normal stomach emptying return, and the body’s tendency to defend a higher weight, the mechanism the trial authors describe as the “chronicity of obesity”, takes over again (STEP 1 trial extension). Regain after stopping is therefore best understood as the underlying condition resurfacing, not a failure of willpower and not a drug-dependency withdrawal in the addiction sense.

Does staying on the medication keep the weight off?

Continuing a GLP-1 medication is what kept the weight off in the trials that tested it head-to-head. In STEP 4, everyone first reached the 2.4 mg semaglutide dose over a 20-week run-in, then was randomized to continue or switch to placebo. From week 20 to week 68, the continued-semaglutide group lost a further 7.9% on average and reached a total loss of about 17.4%, while the group switched to placebo regained weight, gaining 6.9%, a 14.8 percentage-point gap (Rubino et al., STEP 4, JAMA 2021; JAMA full text). Across STEP 4 and SURMOUNT-4, the same result holds for both semaglutide and tirzepatide: continuing maintained and even extended the loss, stopping reversed much of it. That is the clinical basis for treating these medications as ongoing therapy rather than a short course.

Do the health improvements reverse too, or just the weight?

The cardiometabolic improvements largely track the weight, drifting back toward baseline as the pounds return. In the STEP 1 extension, blood pressure that had improved on semaglutide reverted to baseline levels by week 120, and markers such as C-reactive protein and lipids rose again after withdrawal, though several of them (C-reactive protein, HDL cholesterol, and triglycerides) stayed better than in the placebo group at week 120 (STEP 1 trial extension). The tirzepatide data point the same way. In a post hoc analysis of SURMOUNT-4, cardiometabolic risk factors, waist circumference, systolic blood pressure, HbA1c, non-HDL cholesterol, and fasting insulin, worsened in step with how much weight people regained after stopping, and the participants who regained the most saw their earlier improvements reverse the furthest back toward baseline (Horn et al., cardiometabolic-change post hoc analysis of SURMOUNT-4, JAMA Internal Medicine 2025). In other words, the benefits of a GLP-1 are sustained while the treatment and the weight loss are sustained, and they fade together when the weight is regained.

Can you taper or microdose off a GLP-1 without regaining?

There is no randomized trial showing a tapering or “microdosing” schedule that prevents regain, so any lower-dose maintenance plan is an individualized clinical judgment, not a proven protocol. The published withdrawal trials compared continuing the full maintenance dose against stopping altogether, STEP 4 and SURMOUNT-4 both tested continuation versus placebo, not a gradual step-down (STEP 4, JAMA 2021; SURMOUNT-4, JAMA 2024). Some people and their clinicians explore staying on the lowest dose that holds their weight, and the labels do describe a maintenance dose reached by gradual titration (Wegovy Prescribing Information), but the evidence base for a taper that avoids regain is still thin. Our GLP-1 maintenance and microdosing guide covers what is and is not known, and any change to your dose is a conversation to have with a licensed provider rather than a self-directed experiment.

What about side effects and hunger when you stop?

When you stop a GLP-1, the medication’s gastrointestinal side effects tend to ease as the drug clears, while appetite returns, often noticeably. Nausea, vomiting, and diarrhea are among the most common side effects of semaglutide and come from its slowing of gastric emptying; because the drug has an elimination half-life of about a week, it takes several weeks to leave the body after the last dose, and those effects fade over that window (Wegovy Prescribing Information, DailyMed). That same clearance is why hunger and food interest come back and why weight tends to follow (STEP 1 trial extension). These medications are not habit-forming in the way that term is usually meant; the challenge on stopping is the return of the appetite the drug had been suppressing, not a withdrawal syndrome. Planning for that, through nutrition, resistance training, and a maintenance strategy decided with a clinician, is more useful than expecting the results to hold on their own. If muscle preservation is a concern for you, see GLP-1 and muscle loss: how to prevent it.

What this means if you are considering starting or stopping

Treat a GLP-1 as long-term care and plan the exit as carefully as the start. The trial evidence is consistent that weight and its associated health improvements are maintained while treatment continues and are substantially reversed when it stops, which is why obesity medicine frames these drugs as ongoing therapy for a chronic condition rather than a temporary reset (STEP 1 trial extension; SURMOUNT-4, JAMA 2024). Whether continuing, lowering the dose, or stopping is right for you depends on your goals, response, side effects, and health history, a decision a licensed provider makes with you, never a promise made in advance. If you want to compare the two main options before that conversation, read semaglutide vs tirzepatide.

Sources

Every clinical figure on this page traces to a peer-reviewed randomized trial or the FDA-cleared product label. The three withdrawal trials are the primary evidence for what happens when a GLP-1 is stopped or continued.

Advertising disclosure: links marked "Paid link" go to Bodybuilding Peptides (trybbpeptides.com), an affiliate destination, and Modern Weight Medicine may earn a commission if you buy there. Our coverage is independent of that relationship, and nothing on this page is medical or legal advice.